Safety and Efficacy Study in Subjects With Seborrheic Dermatitis

Medicis Global Service Corporation240 enrolled

Overview

The purpose of this study is to determine if two test products are safe and effective in the treatment of seborrheic dermatitis.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

240

Conditions

Seborrheic Dermatitis

Interventions

Test Product 49778DRUG

Test Product 10156DRUG

Vehicle (placebo)DRUG

Eligibility

Sex: ALLMin age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Investigator assessment of seborrheic dermatitis. * Additional criteria as identified in the protocol. Exclusion Criteria: * History of or ongoing psoriasis of the scalp. * History of or ongoing atopic dermatitis of the scalp. * Additional criteria as identified in the protocol.

Locations (22)

Unnamed facility

Fremont, California, United States

Unnamed facility

Los Angeles, California, United States

Outcomes

Primary Outcomes

Symptom Improvement (investigator assessment)

Proportion of subjects with a response of clear or almost clear, and at least a two-grade improvement from baseline to week 4

Time frame: Week 4

Secondary Outcomes

Symptom Improvement (subject assessment)

Assess the change in the pruritus score from baseline to week 2 and to week 4.

Time frame: Weeks 2 and 4

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.